eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
4/2022
vol. 39
 
Share:
Share:
more
 
 
abstract:
Original paper

Omalizumab treatment for chronic spontaneous urticaria: data from Turkey

Rabia Oztas Kara
1
,
Bahar Sevimli Dikicier
1
,
Mahizer Yaldiz
1
,
Busra Koku
1
,
Nur Cihan Çosansu
1
,
Berna Solak
1

1.
Department of Dermatology, Sakarya University Faculty of Medicine, Sakarya, Turkey
Adv Dermatol Allergol 2022; XXXIX (4): 704-707
Online publish date: 2022/09/01
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Aim
The aim of the study was to investigate data from patients suffering from chronic spontaneous urticaria refractory to conventional therapy, and to document outcomes of omalizumab use.

Material and methods
We conducted a single-centre retrospective study with 175 chronic spontaneous urticaria patients who were treated with 300 mg omalizumab subcutaneously every 4 weeks for at least 6 months. Efficacy, factors affecting outcome, and complications were examined.

Results
The complete response rate was 70.9%. Minor complications were observed in 12% of our patients. Anaphylaxis occurred in 1 patient as a major complication. We did not notice any clinical or laboratory factors predicting response to omalizumab treatment.

Conclusions
The findings show that omalizumab is effective and safe for the treatment of chronic spontaneous urticaria with a dosing of 300 mg/month subcutaneously. However, due to 1 case of anaphylaxis in this small group, we must still remind practitioners to be alert for this possible complication.

keywords:

omalizumab, chronic spontaneous, urticaria, treatment

Quick links
© 2022 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.